Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2007

Altair Therapeutics Formed to Exploit Isis IP

  • Altair Therapeutics has been created on the basis of Isis Pharmaceuticals antisense IP. Isis will own 18% of Altair, which will focus on respiratory conditions.

    Under this transaction, Altair gains the exclusive, worldwide license for the development and commercialization of ISIS 369645. The compound is an inhaled inhibitor of the IL-4/IL-13 signaling pathways.

    The companies will also collaborate to discover drugs directed to other targets. Altair will pay Isis development milestones and royalties related to ISIS 369645 and other drugs arising out of the partnership.

    “Altair is assembling a focused team of experts in both antisense drug discovery and development and respiratory conditions to advance antisense drugs including ISIS 369645,” according to Jeff Jonas, M.D., evp of Isis.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »